XMetA, an allosteric monoclonal antibody to the insulin receptor, improves glycaemic control in mice with diet-induced obesity

Diabetes, Obesity and Metabolism

Volumn 15, Issue 3, 2013, Pages 272-275

  Bhaskar, V ^a   Lau, A ^a   Goldfine, I D ^a,b   Narasimha, A J ^a   Gross, L M ^a   Wong, S ^a   Cheung, B ^a   White, M L ^a   Corbin, J A ^a  

^a XOMA Corporation   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Diabetes mellitus; Experimental pharmacology; Glycaemic control; Insulin therapy

Indexed keywords

GLUCOSE; INSULIN RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY XMETA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN RESISTANCE; MOUSE; NONHUMAN; OBESITY;

EID: 84873078765     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12019     Document Type: Article

References (12)

1. National Diabetes Fact Sheet. CDC 2011.
2. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
3. Lyssenko V, Almgren P, Anevski D et al. Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes. Diabetes 2005; 54: 166-174.
4. Vasudevan AR, Garber AJ. Insulin resistance syndrome. A review. Minerva Endocrinol 2005; 30: 101-119.
5. Defronzo RA. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58: 773-795.
6. Leng Y, Karlsson HK, Zierath JR. Insulin signaling defects in type 2 diabetes. Rev Endocr Metab Disord 2004; 5: 111-117.
7. Ussar S, Vienberg SG, Kahn CR. Receptor antibodies as novel therapeutics for diabetes. Sci Transl Med 2011; 3: 113-147.
8. Le Marchand-Brustel Y, Gorden P, Flier JS, Kahn CR, Freychet P. Anti-insulin receptor antibodies inhibit insulin binding and stimulate glucose metabolism in skeletal muscle. Diabetologia 1978; 14: 311-317.
9. Cazorla M, Arrang JM, Premont J. Pharmacological characterization of six trkB antibodies reveals a novel class of functional agents for the study of the BDNF receptor. Br J Pharmacol 2011; 162: 947-960.
10. Bhaskar V, Goldfine ID, Bedinger DH et al. A fully human, allosteric monoclonal antibody that activates the insulin receptor and improves glycemic control. Diabetes 2012; 61: 1263-1271.
11. Vigneri R, Squatrito S, Frittitta L. Selective insulin receptor modulators (SIRM): a new class of antidiabetes drugs? Diabetes 2012; 61: 984-985.
12. Owyang AM, Maedler K, Gross L et al. XOMA 052, an anti-IL-1{beta} monoclonal antibody, improves glucose control and {beta}-cell function in the diet-induced obesity mouse model. Endocrinology 2010; 151: 2515-2527.